货号:A1154812
同义名:
阿特朱单抗
/ MPDL3280A
Atezolizumab是一种人源化IgG1单克隆抗体,通过与PD-L1结合来阻止其与PD-1受体结合。Atezolizumab具有用于多种癌症(如非小细胞肺癌、膀胱癌)研究的潜力。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | PD-1 ↓ ↑ | PD-1/PD-L1 ↓ ↑ | PD-1/PD-L1 interaction ↓ ↑ | PD-L1 ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SR0987 | ✔ | 99% | |||||||||||||||||
| Pembrolizumab | ✔ | 98% | |||||||||||||||||
| Camrelizumab | ✔ | 95% | |||||||||||||||||
| Spartalizumab | ✔ | 95% | |||||||||||||||||
| BMS-1001 |
+
PD-1/PD-L1, EC50: 253 nM |
+
PD-1/PD-L1, EC50: 253 nM |
98% | ||||||||||||||||
| INCB086550 |
++
PD-1/PD-L1, IC50: <10 nM |
++
PD-1/PD-L1, IC50: <10 nM |
98% | ||||||||||||||||
| BMS-1 |
++
PD-1/PD-L1 interaction, IC50: 0.006 μM |
99%+ | |||||||||||||||||
| BMS-202 |
+
PD-1/PD-L1 interaction, IC50: 0.018 μM |
99%+ | |||||||||||||||||
| PD-1/PD-L1-IN 3 |
+++
PD-1/PD-L1 interaction, IC50: 5.6 nM |
98+% | |||||||||||||||||
| Nivolumab |
+++
PD-1/PD-L1 interaction, IC50: 2.52 nM |
95% | |||||||||||||||||
| BMS-1166 |
+++
PD-1/PD-L1 interaction, IC50: 1.4 nM |
99%+ | |||||||||||||||||
| Durvalumab |
++++
PD-1/PD-L1 interaction, IC50: 0.1 nM |
95% | |||||||||||||||||
| Evixapodlin |
++++
PD-1/PD-L1, IC50: 0.213 nM |
95% | |||||||||||||||||
| CA-170 | ✔ | 97% (contains 2.7% ethanol) | |||||||||||||||||
| Atezolizumab |
+++
hPD-L1, Kd: 0.4 nM |
99% | |||||||||||||||||
| AUNP-12 | ✔ | 98% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 产品名称 | PAFR ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ginkgolide B |
+++
PAFR, IC50: 3.6 μM |
99% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 产品名称 | Autophagy ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBI-0206965 |
+++
ULK2, IC50: 711 nM ULK1, IC50: 108 nM |
95% | |||||||||||||||||
| Hydroxychloroquine sulfate | ✔ | 99% | |||||||||||||||||
| Valproic acid sodium | ✔ | HDAC | 97% | ||||||||||||||||
| PFK-015 |
++
PFKFB3, IC50: 207 nM |
99%+ | |||||||||||||||||
| MRT68921 HCl |
++++
ULK2, IC50: 1.1 nM ULK1, IC50: 2.9 nM |
99%+ | |||||||||||||||||
| ROC-325 | ✔ | 99%+ | |||||||||||||||||
| Autophinib |
+++
Autophagy, IC50: 40 nM |
99% | |||||||||||||||||
| Lys05 | ✔ | 99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 蛋白种属 | Human |
| 交叉反应性 | Human,Cynomolgus |
| Isotype | IgG1-Kappa |
| 内毒素 | < 0.001EU/μg, determined by LAL method. |
| 纯化方法 | Purified, Protein A, affinity column |
| 稀释缓冲液 | Sterile PBS or 0.9% saline for reconstitution/dilution. It is recommended to use the reconstituted/diluted product within one month. |
| Concentration | Treated Time | Description | References | |
| 143B cells | 0, 2.5, 5, 10, 20, 40 µg/ml | 24 hours | To evaluate the inhibitory effect of Atezolizumab on the proliferation of 143B cells. Results showed that Atezolizumab inhibited the proliferation of 143B cells in a dose-dependent manner. | Cell Death Dis. 2021 Feb 8;12(2):164. |
| HOS cells | 0, 2.5, 5, 10, 20, 40 µg/ml | 24 hours | To evaluate the inhibitory effect of Atezolizumab on the proliferation of HOS cells. Results showed that Atezolizumab inhibited the proliferation of HOS cells in a dose-dependent manner. | Cell Death Dis. 2021 Feb 8;12(2):164. |
| Administration | Dosage | Frequency | Description | References | ||
| Severe combined immunodeficient mice | HOS cell xenograft tumor model | Intraperitoneal injection | 10 mg/kg | Once daily for 3 weeks | To evaluate the inhibitory effect of Atezolizumab alone or in combination with chloroquine on the growth of HOS xenograft tumors. Results showed that Atezolizumab significantly inhibited tumor growth, and the effect was more pronounced when combined with chloroquine. | Cell Death Dis. 2021 Feb 8;12(2):164. |
| CAS号 | 1380723-44-3 |
| 分子量 | 145.54 kDa |
| SMILES Code | NONE |
| MDL No. | N/A |
| 别名 | 阿特朱单抗 ;MPDL3280A |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C:3-6个月-80°C:24个月 |
沪公网安备 31011702889066号
沪ICP备2024050318号-1